
PROFOUND MEDICAL CORP
PROFNASDAQTrading Snapshot
- Day Range
- $6.91 โ $7.10
- 52-Week Range
- $3.76 โ $8.95
- Volume
- $3.82B
- Avg Volume
- $4.11B
- Shares Outstanding
- 36.3M
- Next Earnings
- Sep 16, 2026
Fundamentals Snapshot
- Annual Revenue
- $16M
- Last Q Revenue
- $2M
- P/E Ratio
- -7.2
- P/S Ratio
- 13.4x
- EPS (TTM)
- $-0.89
- Dividend Yield
- 0.00%
Why Investors Own PROF
- โHigh-growth profile โ revenue up +30.9% YoY with expanding US Equity exposure.
- โHealthy economics โ 77% gross margin and 8% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About PROFOUND MEDICAL CORP
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids โ including through non-invasive methods โ and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.
Otter Score Breakdown
โAnalyst Ratings
โLatest News & Updates

Profound Medical Corp. (PRN:CA) Q2 2026 Earnings Call Transcript
Profound Medical Corp. (PRN:CA) Q2 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsStephen Kilmer - Investor RelationsMatthew Sobczyk -...
Profound Medical Affirms FY2026 Sales Guidance of $25.000M vs $26.858M Est
Profound Medical (NASDAQ:PROF) affirms FY2026 sales outlook from $25.000 million to $25.000 million vs $26.858 million estimate.
Profound Medical Q2 EPS $(0.26), Inline, Sales $2.483M Miss $5.500M Estimate
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.26) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.52) per share from the same period last year. The